×
Model-based Cost-Effectiveness Analyses Comparing Combinations of Urate Lowering Therapy and Anti-Inflammatory Treatment in Newly Diagnosed Gout Patients
https://acrabstracts.org/abstract/model-based-cost-effectiveness-analyses-comparing-combinations-of-urate-lowering-therapy-and-anti-inflammatory-treatment-in-newly-diagnosed-gout-patients/
Celine van de Laar, Martijn A.H. Oude Voshaar, Carly Janssen et. al.

Nov 13th, 2019 - Background/Purpose: To assess the cost-effectiveness of various combinations of urate lowering therapy (ULT) and anti-inflammatory treatment in the management of newly diagnosed gout patients, from the Dutch societal perspective.  Methods: The Anakinra versus Treatment as usual in the Treatment of ACute Gout (ATTACG) study was the  primary data source for  this study.  Since only patients with ...

Machine-learning Classification Identifies a Subset of Patients That Improve on Abatacept via Modulation of a CD28-Related Pathway
https://acrabstracts.org/abstract/machine-learning-classification-identifies-a-subset-of-patients-that-improve-on-abatacept-via-modulation-of-a-cd28-related-pathway/
Bhaven Mehta, Jennifer Franks, Yiwei Yuan et. al.

Nov 13th, 2019 - Background/Purpose: We analyzed a phase 2 study designed to assess the efficacy of abatacept in patients with diffuse Systemic Sclerosis (SSc). In this work, we analyze data from ASSET and seek to confirm the hypothesis that patients in the inflammatory subset on abatacept show a significant decline in modified Rodnan Skin Score (mRSS), which is correlated to modulation of pathways related to t...

Metabolic Signatures of Pathogenic T Cells in Medium and Large Vessel Vasculitis
https://acrabstracts.org/abstract/metabolic-signatures-of-pathogenic-t-cells-in-medium-and-large-vessel-vasculitis/
Mitsuhiro Akiyama, Hui Zhang, Ryu Watanabe et. al.

Nov 13th, 2019 - Background/Purpose: Giant cell arteritis (GCA) is an autoimmune vasculitis that causes aortic arch syndrome, blindnesss, and stroke. Embedded in granulomatous infiltrates, CD4 T cells persist over long periods in the inflamed vessel wall where they drive wall remodeling, intramural neoangiogenesis, intimal hyperplasia and luminal occulsion. To survive and function in a nonlymphoid tissue enviro...

The Role of Bradykinin Receptor B1 and Its New Ligand Soluble CD13 in Rheumatoid Arthritis and Inflammatory Arthritis Mouse Model
https://acrabstracts.org/abstract/the-role-of-bradykinin-receptor-b1-and-its-new-ligand-soluble-cd13-in-rheumatoid-arthritis-and-inflammatory-arthritis-mouse-model/
Chenyang Lu, Phillip Campbell, Jonatan Hervoso et. al.

Nov 13th, 2019 - Background/Purpose: Rheumatoid arthritis (RA) is an inflammatory disorder characterized by synovial hyperplasia, inflammatory cell infiltration and pannus formation. We have shown that soluble CD13 (sCD13) induces angiogenesis, monocyte and lymphocyte chemotaxis and arthritis through G protein-coupled receptors (GPCRs). However, the receptor for sCD13 is not yet defined. Methods: A GPCR screeni...

Lung-Related Factors Are Associated with Transitions from Systemic Anti-CCP Antibody Positivity to Classified RA
https://acrabstracts.org/abstract/lung-related-factors-are-associated-with-transitions-from-systemic-anti-ccp-antibody-positivity-to-classified-ra/
Ashley Visser, Marie Feser, Chelsie Fleischer et. al.

Nov 13th, 2019 - Background/Purpose: Systemic autoimmunity associated with RA precedes the onset of inflammatory arthritis (IA) by several years. In particular, the presence of systemic anti-cyclic citrullinated peptide (CCP) antibody is a strong predictor of developing classified RA in the future. However, the mechanisms involved in the transition from systemic anti-CCP to IA classifiable as RA are unknown. Ou...

Nocturnal Blood Pressure Dipping as a Marker of Endothelial and Cardiac Function in Pediatric-onset Systemic Lupus Erythematosus
https://acrabstracts.org/abstract/nocturnal-blood-pressure-dipping-as-a-marker-of-endothelial-and-cardiac-function-in-pediatric-onset-systemic-lupus-erythematosus/
Joyce Chang, Taylor Goldberg, Sarah McGuire et. al.

Nov 13th, 2019 - Background/Purpose: There is a need for clinically useful measures of cardiovascular (CV) risk in pediatric-onset SLE (pSLE). Nocturnal blood pressure (BP) non-dipping (loss of the physiologic nocturnal decline in BP) is a reversible marker of CV risk and potential treatment target that can be reproducibly measured by ambulatory blood pressure monitoring (ABPM). We assessed the frequency of non...

Knee Injury and Transitions Among States of Knee Osteoarthritis in the Johnston County Osteoarthritis Project: A Multi-State Time-To-Event Modeling Approach
https://acrabstracts.org/abstract/knee-injury-and-transitions-among-states-of-knee-osteoarthritis-in-the-johnston-county-osteoarthritis-project-a-multi-state-time-to-event-modeling-approach/
Yvonne Golightly, Carolina Alvarez, Liubov Arbeeva et. al.

Nov 13th, 2019 - Background/Purpose: Musculoskeletal injury is a known risk factor for osteoarthritis (OA). Cumulative effects of comorbid conditions on the association of injury and OA have not been previously examined. The purpose of this study was to clarify associations between knee injury and radiographic knee osteoarthritis (rKOA) and determine whether associations vary by sex, race, body mass index (BMI)...

Ancestry-Specific Classical HLA Alleles Define Phenotypic Subsets in the African American Scleroderma Population
https://acrabstracts.org/abstract/ancestry-specific-classical-hla-alleles-define-phenotypic-subsets-in-the-african-american-scleroderma-population/
Pravitt Gourh, Sarah Safran, Steven Boyden et. al.

Nov 13th, 2019 - Background/Purpose: Systemic sclerosis (SSc), or scleroderma, is a heterogeneous disease that is divided into limited cutaneous (lcSSc) and diffuse cutaneous (dcSSc) forms based on the extent of skin involvement, and internal organ involvement also adds to phenotypic variability. The three main internal organ complications are interstitial lung disease (ILD), pulmonary arterial hypertension (PA...

Geographic Disparities in Systemic Sclerosis Mortality in the United States: 1999 to 2017
https://acrabstracts.org/abstract/geographic-disparities-in-systemic-sclerosis-mortality-in-the-united-states-1999-to-2017/
Alicia Rodriguez-Pla1 and Robert W Simms, University of Arizona/Banner Health Medical Center, Tucson et. al.

Nov 13th, 2019 - Background/Purpose: Population mortality studies in the United States have previously reported a progressive increase in the scleroderma (SSc) mortality rates from 1959 to 2002. Identification of areas with clusters of higher mortality rates is important to implement targeted interventions and may provide clues about possible etiology factors, especially environmental. In this study, we aimed t...

Go-Dact: A Phase 3b Randomized Double-Blind Placebo-Controled Proof-Of-Concept Trial, of Golimumab Plus Methotrexate (MTX) versus MTX Monotherapy, in Improving Dactylitis, in MTX Naïve Psoriatic Ar...
https://acrabstracts.org/abstract/go-dact-a-phase-3b-randomized-double-blind-placebo-controled-proof-of-concept-trial-of-golimumab-plus-methotrexate-mtx-versus-mtx-monotherapy-in-improving-dactylitis-in-mtx-naive-psoriatic-arthr/
Elsa Vieira-Sousa, Pedro Alves, Ana Maria Rodrigues et. al.

Nov 13th, 2019 - Background/Purpose: Psoriatic arthritis (PsA) dactylitis is associated with an increased risk of erosions and higher disease activity. Dactylitis treatment strategies are however controversial due to the absence of evidence from randomized controlled trials studying dactylitis as a primary outcome. The objective of this trial was to assess the efficacy of golimumab in combination with methotrex...

Increased Expression of Extracellular Matrix Proteins in Human Fibroblast Synoviocytes and Lung Epithelial Cells Following Malondialdehyde-Acetaldehyde Adduct (MAA)/Citrullinated Protein Stimulation
https://acrabstracts.org/abstract/increased-expression-of-extracellular-matrix-proteins-in-human-fibroblast-synoviocytes-and-lung-epithelial-cells-following-malondialdehyde-acetaldehyde-adduct-maa-citrullinated-protein-stimulation/
Matthew O'Dell, Logan Duryee, Lynell Klassen et. al.

Nov 13th, 2019 - Background/Purpose: Recently we have shown that both malondialdehyde-acetaldehyde adducts (MAA) and citrullinated proteins (CIT) are co-localized in joint and lung tissues of patients with rheumatoid arthritis (RA). Therefore, to investigate the possibility that these post-translational modifications pose a synergistic pathogenic role in RA, human synovial fibroblasts and lung epithelial cells ...

Long-term Clinical and Economic Benefits of a Short-term Physical Activity Intervention Among Inactive Knee Osteoarthritis Patients in US: A Model-based Evaluation
https://acrabstracts.org/abstract/long-term-clinical-and-economic-benefits-of-a-short-term-physical-activity-intervention-among-inactive-knee-osteoarthritis-patients-in-us-a-model-based-evaluation/
Genevieve Silva, James Sullivan, Jeffrey Katz et. al.

Nov 13th, 2019 - Background/Purpose: The United States (US) knee osteoarthritis (OA) population has low levels of physical activity (PA), despite its well-defined health benefits. Interventions to promote PA are often stymied by concerns of lack of sustainability of intervention efficacy. We sought to evaluate lifetime benefits and cost-effectiveness of a short term (3-year) PA intervention in this population. ...

Secukinumab Improves Axial Manifestations in Patients with Psoriatic Arthritis and Inadequate Response to NSAIDs: Primary Analysis of Phase 3 Trial
https://acrabstracts.org/abstract/secukinumab-improves-axial-manifestations-in-patients-with-psoriatic-arthritis-and-inadequate-response-to-nsaids-primary-analysis-of-phase-3-trial/
Xenofon Baraliakos, Laura Coates, Laure Gossec et. al.

Nov 13th, 2019 - Background/Purpose: Secukinumab (SEC) has provided significant and sustained improvement in the signs and symptoms of active psoriatic arthritis (PsA) and ankylosing spondylitis1. Evidence is limited on the efficacy of biologics in the treatment of patients (pts) with PsA having axial manifestations that affect between 30–70% of pts2, particularly as validated classification criteria for this s...

Safety and Efficacy Results from the Open Label Extension of a Phase 2 Trial of Risankizumab, a Selective IL-23p19 Inhibitor in Patients with Active Psoriatic Arthritis
https://acrabstracts.org/abstract/safety-and-efficacy-results-from-the-open-label-extension-of-a-phase-2-trial-of-risankizumab-a-selective-il-23p19-inhibitor-in-patients-with-active-psoriatic-arthritis/
Kim Papp, Melinda Gooderham, Akimichi Morita et. al.

Nov 13th, 2019 - Background/Purpose: Psoriatic arthritis (PsA) is characterized by peripheral synovitis, enthesitis, dactylitis and spondylitis, and IL-23 is involved in the pathogenesis of these conditions either directly or indirectly. Risankizumab (RZB), a potent humanized IgG1 monoclonal antibody and selective IL23p19 inhibitor, exhibited superior efficacy vs placebo via ACR responses and PASI scores in pat...

Associations of Socioeconomic Status with Rheumatoid Arthritis (RA) Progression in African Americans with Early Disease
https://acrabstracts.org/abstract/associations-of-socioeconomic-status-with-rheumatoid-arthritis-ra-progression-in-african-americans-with-early-disease/
Rebecca Cleveland, Emma Astrike-Davis, Beth Jonas 1 and Leigh Callahan et. al.

Nov 13th, 2019 - Background/Purpose: In prior cross-sectional analyses of African Americans (AA) with RA, we observed that low education, income and home ownership were associated with clinical damage and patient reported outcomes (PROs) among those with mean disease duration of 7.8 years. However, when restricted to those with disease duration of < 2 years, associations with PROs remained, but were no longer o...

Anakinra Treatment in Patients with Familial Mediterranean Fever: A Single-center Experience
https://acrabstracts.org/abstract/anakinra-treatment-in-patients-with-familial-mediterranean-fever-a-single-center-experience-2/
Serdal Ugurlu, Bugra Han Egeli, Bilgesu Ergezen et. al.

Nov 13th, 2019 - Background/Purpose: The main goal of Familial Mediterranean Fever (FMF) treatment is to prevent attacks and subclinical inflammation. Mainstay of treatment is colchicine; however, 5-10% of patients are unresponsive to colchicine even in maximum tolerated dosage. Anakinra has been proven to be effective in controlled trials in terms of attack frequency and subclinical inflammation in colchicine ...

Advances in Treatment of Rheumatoid Arthritis: ACPA-positive Patients Benefited More Than ACPA-negative Patients; 25 Year Results of a Longitudinal Cohort Study
https://acrabstracts.org/abstract/advances-in-treatment-of-rheumatoid-arthritis-acpa-positive-patients-benefited-more-than-acpa-negative-patients-25-year-results-of-a-longitudinal-cohort-study/
Xanthe ME Matthijssen, Ellis Niemantsverdriet, Thomas Huizinga 2 and Annette van der Helm-van Mil et. al.

Nov 13th, 2019 - Background/Purpose: The last 25 years, treatment of rheumatoid arthritis (RA) has changed considerably. Although clinically relevant joint damage has become infrequent, it is less established to what extent other long-term outcomes have improved. Moreover, anti-citrullinated anti-bodies (ACPA)-positive and ACPA-negative disease subsets were discovered and it is unknown they have benefited equal...

A Randomised, Open Labelled Clinical Trial to Investigate Synovial Mechanisms Determining Response – Resistance to Rituximab versus Tocilizumab in Rheumatoid Arthritis Patients Failing TNF Inhibito...
https://acrabstracts.org/abstract/a-randomised-open-labelled-clinical-trial-to-investigate-synovial-mechanisms-determining-response-resistance-to-rituximab-versus-tocilizumab-in-rheumatoid-arthritis-patients-failing-tnf-inhibitor-t/
Frances humby, Maya H. Buch, Patrick Durez et. al.

Nov 13th, 2019 - Background/Purpose: Although biologic therapies have transformed the outlook for rheumatoid arthritis (RA), the lack of a major treatment response in over 50% of patients, the potential side effects and the high cost of these drugs have highlighted the need to define predictive markers of response and to stratify patients according to therapeutic outcome. B-cells are pivotal to RA pathogenesis,...

Serum Interferon Score Predicts Clinical Outcome at 12 Months in Diffuse Cutaneous Systemic Sclerosis as Measured by Global Ranked Composite Score (GRCS) and Composite Response Index in SSc (CRISS)
https://acrabstracts.org/abstract/serum-interferon-score-predicts-clinical-outcome-at-12-months-in-diffuse-cutaneous-systemic-sclerosis-as-measured-by-global-ranked-composite-score-grcs-and-composite-response-index-in-ssc-criss/
Antonio Carriero, Giuseppina Abignano, MIchelle Hutchinson et. al.

Nov 13th, 2019 - Background/Purpose: Systemic sclerosis (SSc) is a highly heterogeneous disease orphan of effective disease modifying agents. The diffuse cutaneous clinical subset (dcSSc) is currently targeted in most clinical trials. Nevertheless, there is still high variability in clinical outcome within dcSSc, which is limiting effective clinical trial design and interpretation. Global Ranked Composite Score...

Comparison of Malignancy and Mortality Rates Between Tofacitinib and Biologic DMARDs in Clinical Practice: Five-Year Results from a US-Based Rheumatoid Arthritis Registry
https://acrabstracts.org/abstract/comparison-of-malignancy-and-mortality-rates-between-tofacitinib-and-biologic-dmards-in-clinical-practice-five-year-results-from-a-us-based-rheumatoid-arthritis-registry/
Joel Kremer, Clifton Bingham, Laura Cappelli et. al.

Nov 13th, 2019 - Background/Purpose: Real-world evidence (RWE) is key to understanding post-approval long-term safety of medications. Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. A prospective observational 5-year study, embedded within the US Corrona RA registry, was initiated to evaluate the safety of tofacitinib after US Food and Drug Administration approval on Nov 6, 2012. The obje...